Shield Therapeutics plc

Shield Therapeutics plc is a specialized pharmaceutical firm dedicated to developing and commercializing innovative drugs at various clinical stages to address significant unmet medical requirements. Their flagship product, Accrufer/Feraccru, is an oral, non-salt-based treatment specifically designed for adult patients experiencing iron deficiency, with or without associated anemia. The company is also advancing PT20, a novel iron-based phosphate binder that has successfully concluded its pivotal Phase II study for the management of hyperphosphatemia in individuals afflicted with chronic kidney disease. Established in 2008, Shield Therapeutics plc maintains its headquarters in Gateshead, United Kingdom.